Patrick Daly

DocwireNews

Use of an intensified myeloablative conditioning regimen containing thiotepa showed promising efficacy and acceptable safety in patients with severe <a href="https://www.docwirenews.com/page/sickle-cell-disease">sickle cell disease</a> (SCD) undergoing haploidentical hematopoietic stem cell transplantation, according to a poster presentation at the 2024 Tandem Meetings of ASTCT® and CIBMTR®.
The <a href="https://www.astctjournal.org/article/S2666-6367(23)02149-8/abstract" target="_blank" rel="noopener">report</a>, presented by Susan Kelly, MD, from AdventHealth for Children, suggested this novel preparative regimen is a valuable improvement to haploidentical transplants given that less than 20% of patients with SCD have a human leukocyte antigen-identical sibling donor available.
<h2>Thiotepa Improves Haploidentical HSCT for SCD Treatment</h2>
From 2015 to 2023, a total of 28 consecutive patients with severe SCD (SS genotype) received HSCT with the intensified conditioning regimen at two pediatric centers. The cohort had a median age of 14.4 years (range, 5.9-24.8) and was 57% male. Among the transplants, the donor was parent in 57% and sibling in 43%; 90% of donors had sickle cell trait; and the graft source was bone marrow in 80% and peripheral blood in 20%.
The exact conditioning regimen was antithymocyte globulin (0.5 mg/kg on day -9 and 0.2 mg/kg on days -8 to -7), thiotepa (10 mg/kg on day -7), fludarabine 30 mg/m2 (days -6 to -2), cyclophosphamide (14.5 mg/kg on days -6 to -5), and total body irradiation (200 Gy on day -1). Graft-versus-host disease (GVHD) prophylaxis was cyclophosphamide 50 mg/kg/ on days three and four and mycophenolate mofetil starting day five.
The authors stated all patients achieved neutrophil and platelet engraftment at medians of 21.5 days (range, 15-24) and 26.5 days (range, 12-110) respectively, after HSCT. Three patients had secondary graft failure within six months of transplantation, though all three had successful engraftment and were disease free after undergoing a second transplant.
The rates of grade 3 to 4 acute GVHD and moderate-to-severe chronic GVHD were 7.1% (n=2) and 3.5% (n=1), respectively. Additionally, at a median follow-up of 2.5 years, the rates of event-free survival and overall survival were 84% and 95%, respectively.
“Our results are encouraging and support the hypothesis that intensifying the preparative regimen with the addition of myeloablative thiotepa can result in rapid and sustained full donor engraftment with acceptable toxicities and GVHD rates,” Dr. Kelly and colleagues concluded.
More: <a href="https://www.docwirenews.com/post/zahra-pakbaz-md-john-strouse-md-phd-discuss-practicing-classical-hematology">Zahra Pakbaz, MD; John Strouse, MD, PhD, Discuss Practicing Classical Hematology</a>
&nbsp;
Reference
Kelly S, Domm J, Carroll C, et al. Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 Cgy TBI and post-transplant cyclophosphamide. Abstract #409. Presented at the 2024 Tandem Transplantation &amp; Cellular Therapy Meetings of ASTCT® and CIBMTR®; February 21-24, 2024; San Antonio, Texas.

Mark Yarchoan, MD

Feasibility of Personalized Neoantigen Vaccines Plus Pembrolizumab for Advanced HCC

Hepatocellular Carcinoma

David M. Charytan, MD, MSc

Charlotte Robinson

J. Michael Lazarus Distinguished Award Winner David M. Charytan, MD, MsC

NKF Spring Clinical Meetings 2024

Emily Menendez

Modified Gustave Roussey Immune Score Detects ICI Response in BTC

Bile Duct Cancer

Latest News

Myeloablative Conditioning With Thiotepa Improves Haploidentical HSCT in SCD

Sickle Cell Disease

A myeloablative conditioning regimen containing thiotepa had promising efficacy and safety in patients with severe SCD.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Diabetes

Neurology

Rheumatology

Gastroenterology

Pulmonology

Ophthalmology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Fellow on Call

Healthcare Unfiltered

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Career Center

Expert Interviews

Subscribe